

December 3, 2014



## Corbus Pharmaceuticals to Present at the Oppenheimer 25th Annual Healthcare Conference on December 10, 2014

**Live Webcast on Wednesday, December 10, at 8:35 a.m. EST**

NORWOOD, MA -- (Marketwired) -- 12/03/14 -- [Corbus Pharmaceuticals Holdings, Inc.](#) (OTCQB: CRBP) (the "Company"), an emerging drug development company focused on the development and commercialization of its lead product candidate, [Resunab](#)<sup>™</sup>, for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today it will be presenting at the [Oppenheimer & Co. 25th Annual HealthCare Conference](#) being held December 10-11, 2014, at the Crowne Plaza Hotel in New York, New York.

The Company's Chief Executive Officer, Yuval Cohen, Ph.D., is scheduled to present a corporate overview on Wednesday, December 10, 2014, at 8:35 a.m. Eastern Standard Time. The presentation will include an update on the clinical development of Resunab, the Company's lead rare disease product candidate. Resunab is a novel synthetic oral specialized pro-resolving mediator (SPM) drug with unique anti-inflammatory and anti-fibrotic activity. The Company is developing Resunab for therapeutic indications in cystic fibrosis (CF) and diffuse cutaneous systemic sclerosis (scleroderma).

A live webcast of the presentation will be available on the Company's corporate website ([www.CorbusPharma.com](http://www.CorbusPharma.com)) by accessing the [IR Calendar](#) in the [News and Events](#) section of the Company's [Investor Relations](#) page. A webcast replay will be available approximately two hours after the presentation ends and will be accessible for one month.

### **About Resunab<sup>™</sup>**

Resunab<sup>™</sup> is a novel synthetic oral drug with unique anti-inflammatory and anti-fibrotic activity. Pre-clinical and Phase 1 studies have shown Resunab to have a favorable safety profile coupled with promising potency in pre-clinical models of inflammation and fibrosis. Resunab binds to the CB2 receptor of immune cells and triggers a process known as "inflammatory resolution," in effect turning chronic inflammation "off."

### **About Corbus Pharmaceuticals**

Corbus Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare life-threatening inflammatory-fibrotic diseases with clear unmet medical needs. Our lead product candidate Resunab is a novel oral anti-inflammatory drug scheduled to commence Phase 2 clinical

trials for the treatment of cystic fibrosis and diffuse scleroderma in 2015. For more information, please visit [www.CorbusPharma.com](http://www.CorbusPharma.com).

### ***Forward-Looking Statements***

This press release contains certain forward-looking statements, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. Additional written and oral forward-looking statements may be made by the Company from time to time in filings with the Securities and Exchange Commission or otherwise. The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would," "will" and similar expressions and the negatives of those terms. These statements involve known and unknown risks, uncertainties, and other factors, including the statements set forth under "Expected Near-Term Milestones," which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

### ***Investor and Media Contact***

Jenene Thomas

Investor Relations and Corporate Communications Advisor

Jenene Thomas Communications, LLC

Phone: +1 (908) 938-1475

Email: [Email Contact](#)

Source: Corbus Pharmaceuticals Holdings, Inc.